Published in Gut on September 01, 1982
In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob Agents Chemother (1989) 1.90
Comparison of properties of woodchuck hepatitis virus and human hepatitis B virus endogenous DNA polymerases. Antimicrob Agents Chemother (1984) 1.18
Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection. Gut (1985) 0.98
Activities of arabinosyladenine monophosphate and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against ground squirrel hepatitis virus in vivo as determined by reduction in serum virion-associated DNA polymerase. Antimicrob Agents Chemother (1985) 0.89
Psychosocial impact of chronic infection with hepatitis B virus on British patients. Genitourin Med (1985) 0.80
T cell subsets in chronic hepatitis B and the effect of prednisolone withdrawal and interferon alpha-2b. Korean J Intern Med (1999) 0.77
Antiviral treatment in chronic infection with hepatitis B virus. Br Med J (Clin Res Ed) (1986) 0.75
Antiviral treatment of chronic hepatitis B virus infection. J R Soc Med (1984) 0.75
Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection. Antimicrob Agents Chemother (1986) 0.75
Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem (1966) 21.70
Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med (1976) 2.67
DNA and DNA polymerase in the core of the Dane particle of hepatitis B. Am J Med Sci (1976) 2.24
Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology (1980) 2.04
Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. Gastroenterology (1981) 1.38
Effect of vidarabine on chronic hepatitis B virus infection. JAMA (1978) 1.34
Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside. Hepatology (1981) 1.29
Natural history of liver disease in chronic hepatitis B surface antigen carriers. Survey of 100 patients from Great Britain. Lancet (1981) 1.24
HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine. Br Med J (1978) 1.15
A radioimmunoassay for HBcAg in the sera of HBsAg carriers: serum HBcAg, liver HBcAg immunofluorescence as markers of chronic liver disease. Gastroenterology (1981) 1.15
Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications. Clin Exp Immunol (1966) 8.26
Prevalence of antibodies to human immunodeficiency virus, gonorrhoea rates, and changed sexual behaviour in homosexual men in London. Lancet (1987) 7.71
Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature (1985) 6.65
The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med (1973) 6.65
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23
Increase in primary liver cancer in the UK, 1979-94. Lancet (1997) 6.15
Vaccine-induced escape mutant of hepatitis B virus. Lancet (1990) 5.31
Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain. Lancet (1984) 5.20
Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet (1972) 5.17
Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet (1989) 5.16
Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut (1980) 4.09
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet (1996) 4.05
Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A (1996) 4.02
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut (2002) 4.01
Gonorrhoea in homosexual men and media coverage of the acquired immune deficiency syndrome in London 1982-3. Br Med J (Clin Res Ed) (1984) 3.95
Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med (1995) 3.54
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut (2001) 3.45
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology (1998) 3.31
Natural history of early primary biliary cirrhosis. Lancet (1996) 3.24
Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med (1971) 3.23
Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet (1968) 3.10
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
The epidemiology of testicular cancer in young adults. Am J Epidemiol (1980) 2.90
Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS (1997) 2.88
The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. Q J Med (1979) 2.84
Spread of acute type-B hepatitis in London. Lancet (1973) 2.82
Rising prevalence of human T-lymphotropic virus type III (HTLV-III) infection in homosexual men in London. Lancet (1985) 2.72
Measurement of liver-iron concentration in needle-biopsy specimens. Lancet (1971) 2.65
Arterial changes in the lungs in cirrhosis of the liver--lung spider nevi. N Engl J Med (1966) 2.65
Relationship of hepatitis-associated antigen (H.A.A.) to acute and chronic liver injury. Lancet (1971) 2.61
Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology (1994) 2.60
Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum. Lancet (1970) 2.60
Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology (1975) 2.58
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet (2000) 2.58
Hepatitis C virus: evidence for sexual transmission. BMJ (1991) 2.50
The induction of tolerance to a soluble protein antigen by oral administration. Immunology (1974) 2.50
Failure to deliver hepatitis B vaccine: confessions from a genitourinary medicine clinic. BMJ (1991) 2.49
Partial nodular transformation of the liver with portal hypertension. Am J Med (1966) 2.45
Cell-mediated immunity in patients positive for hepatitis-associated antigen. Br Med J (1972) 2.39
Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. J Pediatr (1993) 2.32
A randomized trial of percutaneous transhepatic cholangiography with the Chiba needle versus endoscopic retrograde cholangiography for bile duct visualization in jaundice. Gastroenterology (1976) 2.25
Diagnosis of Gilbert's syndrome: role of reduced caloric intake test. Br Med J (1973) 2.21
Detection of human herpesvirus 8 DNA in semen from HIV-infected individuals but not healthy semen donors. AIDS (1997) 2.20
Impaired delayed hypersensitivity in primary biliary cirrhosis. Lancet (1969) 2.19
Is primary biliary cirrhosis an immune complex disease? Lancet (1977) 2.15
Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology (1989) 2.15
Role of the liver in controlling the immunogenicity of commensal bacteria in the gut. Lancet (1973) 2.15
The pancreas in primary biliary cirrhosis and primary sclerosing cholangitis. Gastroenterology (1982) 2.11
Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med (1983) 2.10
Complications of diuretic therapy in hepatic cirrhosis. Lancet (1966) 2.09
Hereditary spherocytosis with secondary haemochromatosis. Lancet (1968) 2.00
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology (1994) 2.00
Prophylactic oral acyclovir in recurrent genital herpes. Lancet (1984) 1.99
Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology (1997) 1.94
Immune complexes in acute and chronic liver disease. Clin Exp Immunol (1978) 1.93
The pathology of hepatitis C. Hepatology (1992) 1.92
Evidence for a cerebral effect of the hepatitis C virus. Lancet (2001) 1.90
Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet (1988) 1.90
Incidence and clinical significance of e antigen and antibody in acute and chronic liver disease. Lancet (1975) 1.90
Human immunodeficiency viruses in patients attending a sexually transmitted disease clinic in London, 1982-7. BMJ (1989) 1.89
Sex-related differences among 100 patients with alcoholic liver disease. Br Med J (1977) 1.89
Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun (2003) 1.88
Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: three years experience in a London hospital. Q J Med (1989) 1.88
Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet (1978) 1.86
Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology (1998) 1.84
Hepatitis-associated antigen in chronic liver disease. Lancet (1969) 1.82
Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med (1996) 1.82
The detection of HBV-DNA in serum by molecular hybridisation: a more sensitive method for the detection of complete HBV particles. J Med Virol (1982) 1.81
Association of primary sclerosing cholangitis with HLA-B8. Gut (1983) 1.79
Hemolytic anemia in Wilson's disease. N Engl J Med (1967) 1.78
Incidence and prognostic importance of jaundice after cardiopulmonary bypass surgery. Lancet (1983) 1.78
Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet (1997) 1.71
Validity and reliability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of life. Dig Liver Dis (2005) 1.69
Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut (2000) 1.68
HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet (1995) 1.67
Bone disease and calcium absorption in primary biliary cirrhosis with special reference to vitamin-D therapy. Lancet (1968) 1.67
Primary sclerosing cholangitis, the biliary tree, and ulcerative colitis. Gut (1967) 1.67
Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders. Gut (1981) 1.67
The Budd-Chiari syndrome: correlation between hepatic scintigraphy and the clinical, radiological, and pathological findings in nineteen cases of hepatic venous outflow obstruction. Gastroenterology (1975) 1.66
Presentation and course of asymptomatic primary biliary cirrhosis. Gastroenterology (1977) 1.65
Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci U S A (1991) 1.64
Immunological studies in an epidemic of infective, short-incubation hepatitis. Lancet (1972) 1.62
Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci U S A (1988) 1.62
Effects of cyclosporin A on suppressor and inducer T lymphocytes in primary biliary cirrhosis. Lancet (1980) 1.61
Thymus-dependent lymphocyte function in patients with hepatitis-associated antigen. Lancet (1972) 1.60
Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet (1971) 1.60
Natural history of hepatitis-associated antigen-positive chronic liver disease. Lancet (1972) 1.59
Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis. Gut (1986) 1.58
Arsenic and noncirrhotic portal hypertension. Gastroenterology (1974) 1.57